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Abstract
The purpose of this study was to describe pregnancy outcomes in
female liver recipients transplanted under the age of 21. Data were
collected from the National Transplantation Pregnancy Registry
(NTPR) via questionnaires, phone interviews and medical records.
There were a total of 151 liver recipients who reported 261
pregnancies to the NTPR. Of these recipients, 57 were transplanted
under the age of 21. There were 109 pregnancies with 111 pregnancy
outcomes (including 2 sets twins). The mean age at transplant was
16.6±4.3 yrs with a range of 0.8-20.9 yrs and the mean age at
conception was 24.5±4.1 yrs. There were 83 (75%) livebirths, 16 (14%)
spontaneous abortions, 9 (8%) therapeutic abortions, 2 (2%)
stillbirths, and 1 (1%) ectopic pregnancy reported. The mean
transplant to conception interval was 7.7±5.3 yrs; range 0.4-19.9 yrs.
Immunosuppression during pregnancy included: cyclosporine-based
in 63 (Sandimmune® 37, Neoral® 19, Gengraf® 7), tacrolimus
(Prograf®)-based in 38 and no immunosuppression in 8.
Mycophenolate mofetil (MMF) was used as adjunctive therapy for 9
pregnancies. Comorbid conditions reported during pregnancy
included: drug-treated hypertension 32%, infections 30%,
preeclampsia 16%, diabetes 7%, and rejection 5%. Six recipients
(10.5%) lost their graft within 2 years of delivery. Follow-up of the
mothers 6.8 4.6 yrs. postpartum revealed 40 recipients with adequate
graft function, 3 with reduced/poor function; 8 recipients (14%) had
died and 6 were lost to follow-up. The mean gestational age of the
newborn was 36.5±3.5 wks; 44% were premature; mean birthweight
was 2626±753 g; 37% were low birthweight (<2500 g). There were 5
(6%) birth defects reported: multiple anomalies n=2 (both infants
died; maternal immunosuppression included MMF), total anomalous
pulmonary venous return n=1 (maternal immunosuppression
included MMF), pyloric stenosis n=1, and hypospadias n=1. The
majority of the children were healthy and developing well with a mean
age of 5.9 yrs. at last follow-up.
Conclusions: Liver recipients transplanted under the age of 21 are
able to maintain pregnancy with 75% resulting in a livebirth.
Pregnancy, potential risks for mother and newborn, and long-term
maternal survival should be discussed with the recipient and the
parents of the recipient. Transplant centers are encouraged to report
pregnancy outcomes in these recipients to the NTPR.

Purpose
The purpose of this study was to describe pregnancy
outcomes in female liver recipients transplanted
under the age of 21 who reported to the National
Transplantation Pregnancy Registry (NTPR).

Methods
Data were collected via questionnaires, phone
interviews and medical records.
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Results

Maternal Conditions During Pregnancy

• 151 liver recipients reported 261 pregnancies to
•
•
•
•

the NTPR
Of these recipients, 57 were transplanted under
the age of 21
There were 109 pregnancies with 111 pregnancy
outcomes (including 2 sets twins)
Mean age at transplant was 16.6 ± 4.3 yrs
- range 0.8 - 20.9 yrs
Mean age at conception 24.5 ± 4.1 yrs

Maternal Graft Function
• Graft function at last follow-up (n=57):

Hypertension

32%

Infection

30%

Preeclampsia

16%

Diabetes

7%

Rejection

5%

(mean 6.8 ± 4.6 yrs)
- adequate n=40
- reduced/poor function n=3
- recipient death n=8
- lost to follow-up n=6

Conclusions
• Liver recipients transplanted under the

Pregnancy Outcomes*
Livebirths
Spontaneous abortions

83 (75%)
16 (14%)

Therapeutic abortions

9 (8%)

Stillbirths

2 (2%)

Ectopic pregnancies

1 (1%)

Total

111

*Includes twins

Maternal Immunosuppression
During 109 Pregnancies
• Cyclosporine based n=63
Sandimmune®

Newborn Outcomes

n=37
- Neoral® n=19
- Gengraf® n=7
• Tacrolimus (Prograf®) based n=38
• No immunosuppression n=8
• Mycophenolate mofetil (CellCept®, MMF) was
used as adjunctive therapy in 9 pregnancies

•
•
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•
•

n = 83
Mean gestational age 36.5 ± 3.5 wks
Premature (<37 wks) 44%
Mean birthweight 2,626 ± 753 g
Low birthweight (<2500 g) 37%

Structural Birth Defects
• At last follow-up, the majority of the children
were reported healthy and developing well with
a mean age of 5.9 yrs.
• The total number of liveborn with birth defects
among offspring was 5 of 83 children for an
incidence of 6%.

• Birth defects included:
- pyloric stenosis (n=1)
- hypospadias (n=1)
- total anomalous pulmonary venous return (n=1)
(maternal immunosuppression included MMF)

• Two infants with multiple anomalies died
(maternal immunosuppression included MMF)

age of 21 are able to maintain pregnancy
with 75% resulting in a livebirth.

• Pregnancy, potential risks for mother and
newborn, and long-term maternal survival
should be discussed with the recipient
and the parents of the recipient.

• Transplant centers are encouraged to
report pregnancy outcomes in these
recipients to the NTPR.
To contact the NTPR and report additional
pregnancies:
Thomas Jefferson University
1025 Walnut Street, 605 College Building,
Philadelphia, PA 19107, USA
Phone: Toll-free 877-955-6877; 215-955-4820;
fax 215-923-1420
Email: NTPR.Registry@jefferson.edu
Website: http://www.jefferson.edu/ntpr
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